aTyr Pharma (NASDAQ:LIFE) Stock Rating Lowered by StockNews.com

aTyr Pharma (NASDAQ:LIFE – Get Rating) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Tuesday. Separately, Zacks Investment Research raised aTyr Pharma from a “hold” rating to a “buy” rating and set a $6.75 target price for the company in a research report on Friday, […]

Related Keywords

San Diego ,California ,United States ,Paul Schimmel ,Atyr Pharma Inc ,Qube Research Technologies Ltd ,Charles Schwab Investment Management Inc ,Goldman Sachs Group Inc ,Zacks Investment Research ,Sheaff Brock Investment Advisors ,Tyr Pharma ,Get Rating ,Schwab Investment Management ,Brock Investment Advisors ,Technologies Ltd ,Goldman Sachs Group ,Xiang Lei Yang ,Bruce Beutler ,Atyr Pharma ,Nasdaq Life ,Life ,Medical ,53217v10 ,Downgrade ,Stocknews Com ,